Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
Conditions: Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Interventions: Drug: Adebrelimab; Drug: Apatinib; Drug: Tegafur Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Esophagus Cancer | Hospitals | Immunotherapy | Research | Skin Cancer | Squamous Cell Carcinoma